{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:52:52Z","timestamp":1791211972671,"version":"4.1.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.annonc.2025.01.022","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T08:03:28Z","timestamp":1738915408000},"page":"361-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["European Myeloma Network Group review and consensus statement on primary plasma cell leukemia"],"prefix":"10.1016","volume":"36","author":[{"given":"P.","family":"Musto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-1676","authenticated-orcid":false,"given":"M.","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"E.","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"C.","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sgherza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Katodritou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Royer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-4157","authenticated-orcid":false,"given":"D.","family":"Derudas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Caers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3677-4804","authenticated-orcid":false,"given":"M.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"H\u00e1jek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-V.","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2025.01.022_bib1","series-title":"Wiener Klinische Wochenschrift","first-page":"336","article-title":"Laeucaemia lymphatica plasmacellularis","author":"Gluzinski","year":"1906"},{"issue":"5","key":"10.1016\/j.annonc.2025.01.022_bib2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archinte.133.5.813","article-title":"Plasma cell leukemia. Report on 17 cases","volume":"133","author":"Kyle","year":"1974","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.022_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.leukres.2008.06.027","article-title":"Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia","volume":"33","author":"Chang","year":"2009","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.022_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.critrevonc.2011.04.005","article-title":"Primary plasma cell leukemia in the era of new drugs: has something changed?","volume":"82","author":"Musto","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.annonc.2025.01.022_bib5","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2012.107","article-title":"Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols","volume":"26","author":"Usmani","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.022_bib6","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1182\/blood-2012-05-408682","article-title":"How I treat plasma cell leukemia","volume":"120","author":"van de Donk","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ejh.12533","article-title":"Plasma cell leukemia: from biology to treatment","volume":"95","author":"Jelinek","year":"2015","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.annonc.2025.01.022_bib8","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17474086.2016.1244002","article-title":"Primary plasma cell leukemia 2.0: advances in biology and clinical management","volume":"9","author":"Neri","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.022_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/17474086.2019.1598258","article-title":"An update on biology, diagnosis and treatment of primary plasma cell leukemia","volume":"12","author":"Musto","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.022_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-021-00414-6","article-title":"A\u00a0clinical perspective on plasma cell leukemia; current status and future directions","volume":"11","author":"Tuazon","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.annonc.2025.01.022_bib11","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s11912-024-01563-0","article-title":"Current status on management of primary plasma cell leukemia","volume":"26","author":"Gong","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.022_bib12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.022_bib13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","article-title":"Trends in survival of patients with primary plasma cell leukemia: a population-based analysis","volume":"124","author":"Gonsalves","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.022_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41375-023-02100-x","article-title":"Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States","volume":"38","author":"Saba","year":"2024","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.annonc.2025.01.022_bib15","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/cncr.22700","article-title":"Efficacy and safety of bortezomib in patients with plasma cell leukemia","volume":"109","author":"Musto","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2025.01.022_bib16","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdq646","article-title":"Primary plasma cell leukemia: a retrospective multicenter study of 73 patients","volume":"22","author":"Pagano","year":"2011","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.01.022_bib17","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3324\/haematol.2009.013334","article-title":"Primary plasma cell leukemia and autologous stem cell transplantation","volume":"95","author":"Drake","year":"2010","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.annonc.2025.01.022_bib18","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/blood.V118.21.2008.2008","article-title":"Has allogeneic transplantation a role in the management of plasma cell leukaemia? A study on behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT","volume":"118","author":"Morris","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.annonc.2025.01.022_bib19","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/leu.2011.312","article-title":"Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research","volume":"26","author":"Mahindra","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/leu.2011.176","article-title":"Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience","volume":"26","author":"Avet-Loiseau","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.022_bib21","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/annonc\/mdr480","article-title":"Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party","volume":"23","author":"D\u2019Arena","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.022_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.23600","article-title":"Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group","volume":"89","author":"Katodritou","year":"2014","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.022_bib23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cncr.31718","article-title":"Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents","volume":"125","author":"Mina","year":"2019","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2025.01.022_bib24","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41409-018-0392-1","article-title":"Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs","volume":"54","author":"Gowda","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.01.022_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-141525","article-title":"Outcomes of plasma cell leukemia patients in the era of next-generation novel agents: a single-center retrospective cohort study","volume":"136","author":"Ge","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.022_bib26","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1038\/s41375-020-0830-0","article-title":"Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era","volume":"34","author":"Dhakal","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.022_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2991\/chi.k.200706.002","article-title":"Plasma cell leukemia - facts and controversies: more questions than answers?","volume":"2","author":"Suska","year":"2020","journal-title":"Clin Hematol Int"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.022_bib28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.mayocp.2020.06.060","article-title":"Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of novel agent therapy","volume":"96","author":"Nandakumar","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.annonc.2025.01.022_bib29","article-title":"Practical management and assessment of primary plasma cell leukemia in the novel agent era","volume":"28","author":"Visram","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.022_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-021-00415-5","article-title":"First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018","volume":"11","author":"Brink","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.022_bib31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3324\/haematol.2021.280568","article-title":"Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling","volume":"108","author":"Lawless","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.022_bib32","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1080\/10428194.2023.2171266","article-title":"Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group","volume":"64","author":"Pe\u00f1a","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.annonc.2025.01.022_bib33","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ajh.26891","article-title":"Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: a multicenter study by the Greek myeloma study group","volume":"98","author":"Katodritou","year":"2023","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.annonc.2025.01.022_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41408-022-00755-w","article-title":"Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party","volume":"12","author":"Jung","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.annonc.2025.01.022_bib35","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1016\/S2152-2650(23)02048-7","article-title":"P-431 Clinical characteristics, prognostic factors and treatment outcomes in patients diagnosed with primary plasma cell leukemia based on the revised criteria (KMM2204)","volume":"23","author":"Jung","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2254556","article-title":"Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study","volume":"28","author":"Guan","year":"2023","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/j.annonc.2025.01.022_bib37","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1007\/s00277-024-05862-1","article-title":"Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study","volume":"103","author":"Deng","year":"2024","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.annonc.2025.01.022_bib38","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.3390\/cancers16112149","article-title":"A\u00a0clinical perspective on plasma cell leukemia: a single-center experience","volume":"16","author":"Li","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.01.022_bib39","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1182\/blood-2024-200267","article-title":"Impact of multiple high-risk cytogenetic abnormalities on the survival outcomes of patients with primary plasma cell leukemia","volume":"144","author":"Almodovar Diaz","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.annonc.2025.01.022_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70192","article-title":"Poor outcome despite modern treatments: a retrospective study of 99 patients with primary and secondary plasma cell leukemia","volume":"13","author":"Tessier","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.annonc.2025.01.022_bib41","article-title":"Outcomes of hematopoietic stem cell transplantation in primary plasma cell leukemia: a systematic review and meta-analysis","volume":"148","author":"Shahzad","year":"2024","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.022_bib42","first-page":"225","article-title":"Survival outcomes of patients with primary plasma cell leukemia in the era of proteasome inhibitors and immunomodulatory agents: a real-life multicenter analysis","volume":"41","author":"Ata\u015f","year":"2024","journal-title":"Turk J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.01.022_bib43","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1182\/blood-2024-207270","article-title":"Optimal treatment for newly diagnosed primary plasma cell leukemia: a retrospective multicenter analysis","volume":"144","author":"Venkatesh","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.01.022_bib44","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1182\/blood-2024-206283","article-title":"Evaluation of characteristics and outcomes of patients with primary and secondary plasma cell leukemia treated with modern therapies","volume":"144","author":"Broughton","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clml.2024.10.014","article-title":"Clinical characteristics and survival outcomes of patients with primary and secondary plasma cell leukemia according to the 2021 definition: a single center retrospective study","volume":"25","author":"Shalaby","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/leu.2013.241","article-title":"Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia","volume":"28","author":"Musto","year":"2014","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.annonc.2025.01.022_bib47","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","article-title":"Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du My\u00e9lome","volume":"34","author":"Royer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.01.022_bib48","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(23)00405-9","article-title":"Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12\/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study","volume":"24","author":"van de Donk","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.01.022_bib49","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/s41375-018-0209-7","article-title":"European myeloma network recommendations on diagnosis and management of patients\u00a0with rare plasma cell dyscrasias","volume":"32","author":"Gavriatopoulou","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.022_bib50","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.annonc.2025.01.022_bib51","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2147\/CLEP.S99463","article-title":"The Danish National Multiple Myeloma Registry","volume":"8","author":"Gimsing","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.14735\/amko201947","article-title":"Epidemiology of plasma cell leukemia in the Czech Republic","volume":"32","author":"Zapletalova","year":"2019","journal-title":"Klin Onkol"},{"issue":"19","key":"10.1016\/j.annonc.2025.01.022_bib53","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.022_bib54","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","article-title":"Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition","volume":"102","author":"Granell","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.022_bib55","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-018-0140-1","article-title":"Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.annonc.2025.01.022_bib56","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1016\/S2152-2650(23)02047-5","article-title":"Incidence of primary plasma cell leukemia with the new diagnostic criteria","volume":"23","author":"Jano","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib57","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/10428194.2018.1473574","article-title":"Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients","volume":"60","author":"Jurczyszyn","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.022_bib58","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clml.2022.12.002","article-title":"The current state of knowledge about evolution of multiple myeloma to plasma cell leukemia","volume":"23","author":"Jurczyszyn","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.022_bib59","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/biomedicines10020209","article-title":"The cytogenetic profile of primary and secondary plasma cell leukemia: etiopathogenetic perspectives, prognostic impact and clinical relevance to newly diagnosed multiple myeloma with differential circulating clonal plasma cells","volume":"10","author":"Papadhimitriou","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.022_bib60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.annonc.2025.01.022_bib61","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.01.022_bib62","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1182\/blood-2024-210379","article-title":"Real-world confirmatory analysis of the current IMWG diagnostic criteria identifies early transformation as major risk factor in plasma cell leukemia","volume":"144","author":"Peter","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.022_bib63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.022_bib64","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","article-title":"Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics","volume":"93","author":"Garc\u0131\u0301a-Sanz","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.022_bib65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.leukres.2010.04.021","article-title":"Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia","volume":"35","author":"Kraj","year":"2011","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib66","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.17713","article-title":"Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia","volume":"195","author":"Bezdekova","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.022_bib67","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/(SICI)1098-2264(199706)19:2<124::AID-GCC8>3.0.CO;2-0","article-title":"Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization","volume":"19","author":"Avet-Loiseau","year":"1997","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.022_bib68","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.V97.3.822","volume":"97","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.annonc.2025.01.022_bib69","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.annonc.2025.01.022_bib70","doi-asserted-by":"crossref","first-page":"17514","DOI":"10.3390\/ijms160817514","article-title":"Molecular classification and pharmacogenetics of primary plasma cell leukemia: an initial approach toward precision medicine","volume":"16","author":"Simeon","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ajh.23339","article-title":"Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles","volume":"88","author":"Mosca","year":"2013","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.022_bib72","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/cancers14061594","article-title":"Genomics of plasma cell leukemia","volume":"14","author":"Rojas","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.022_bib73","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/humu.1177","article-title":"High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis","volume":"18","author":"Bezieau","year":"2001","journal-title":"Hum Mutat"},{"issue":"27","key":"10.1016\/j.annonc.2025.01.022_bib74","doi-asserted-by":"crossref","first-page":"24205","DOI":"10.18632\/oncotarget.4434","article-title":"Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation","volume":"6","author":"Lionetti","year":"2015","journal-title":"Oncotarget"},{"issue":"28","key":"10.1016\/j.annonc.2025.01.022_bib75","doi-asserted-by":"crossref","first-page":"26129","DOI":"10.18632\/oncotarget.4674","article-title":"A\u00a0compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias","volume":"6","author":"Lionetti","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.022_bib76","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjh.13793","article-title":"Compendium of FAM46C gene mutations in plasma cell dyscrasias","volume":"174","author":"Barbieri","year":"2016","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.annonc.2025.01.022_bib77","doi-asserted-by":"crossref","first-page":"21353","DOI":"10.18632\/oncotarget.7241","article-title":"Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature","volume":"7","author":"Lionetti","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.022_bib78","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.annonc.2025.01.022_bib79","doi-asserted-by":"crossref","first-page":"17543","DOI":"10.18632\/oncotarget.4028","article-title":"Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns","volume":"6","author":"Cifola","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.022_bib80","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-12-3461","article-title":"Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome","volume":"19","author":"Todoerti","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.022_bib81","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-019-0253-1","article-title":"Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background","volume":"9","author":"Rojas","year":"2019","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.022_bib82","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1158\/1078-0432.CCR-12-2043","article-title":"Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia","volume":"19","author":"Lionetti","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.022_bib83","doi-asserted-by":"crossref","first-page":"14814","DOI":"10.18632\/oncotarget.7442","article-title":"Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma","volume":"7","author":"Ronchetti","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2025.01.022_bib84","first-page":"7395","article-title":"Global methylation patterns in primary plasma cell leukemia","author":"Todoerti","year":"2018","journal-title":"Leuk Res"},{"issue":"17","key":"10.1016\/j.annonc.2025.01.022_bib85","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood.2021014968","article-title":"Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features","volume":"139","author":"Cazaubiel","year":"2022","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.annonc.2025.01.022_bib86","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.3390\/cancers13194898","article-title":"Transcriptomic analysis in multiple myeloma and primary plasma cell leukemia with t(11;14) reveals different expression patterns with biological implications in venetoclax sensitivity","volume":"13","author":"Todoerti","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.01.022_bib87","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood-2023-179646","article-title":"Distinct genetic features in peripheral blood represent the characteristics of circulating plasma cells in primary plasma cell leukemia","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.022_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.46989\/001c.87755","article-title":"Racial disparities in plasma cell leukemia outcomes among hospitalized patients in the United States","volume":"5","author":"Wu","year":"2023","journal-title":"Clin Hematol Int"},{"issue":"7","key":"10.1016\/j.annonc.2025.01.022_bib89","first-page":"1523","article-title":"Clinical and laboratory characteristics of IgM primary plasma cell leukemia","volume":"69","author":"Wu","year":"2023","journal-title":"Clin Lab"},{"key":"10.1016\/j.annonc.2025.01.022_bib90","article-title":"IgE plasma cell leukemia harboring t(11;14) and 1q amplification","volume":"2023","author":"Nakahara","year":"2023","journal-title":"Case Rep Hematol"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.022_bib91","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjh.15092","article-title":"Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients","volume":"180","author":"Jurczyszyn","year":"2018","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.annonc.2025.01.022_bib92","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.2016.66.6115","article-title":"Progress in the treatment of primary plasma cell leukemia","volume":"34","author":"Musto","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.01.022_bib93","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3324\/haematol.2022.281432","article-title":"Plasma cell leukemia: another piece of the puzzle","volume":"108","author":"Musto","year":"2023","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.022_bib94","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.01.022_bib95","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.clml.2021.01.002","article-title":"Efficacy of daratumumab-based regimens for the treatment of plasma cell leukemia","volume":"21","author":"Parrondo","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"10.1016\/j.annonc.2025.01.022_bib96","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"46","key":"10.1016\/j.annonc.2025.01.022_bib97","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040447","article-title":"Selinexor in combination with pomalidomide and dexamethasone for the treatment of primary plasma cell leukemia with 1q21+ abnormality: a case report","volume":"103","author":"Fan","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.022_bib98","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ejh.12986","article-title":"Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)","volume":"100","author":"Gonsalves","year":"2018","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib99","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1002\/ajh.25331","article-title":"Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)","volume":"94","author":"Jelinek","year":"2019","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.annonc.2025.01.022_bib100","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.1002\/ajh.25676","article-title":"The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia","volume":"95","author":"Nalghranyan","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.022_bib101","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/10428194.2021.2010065","article-title":"Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression","volume":"63","author":"Roy","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.annonc.2025.01.022_bib102","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1080\/10428194.2024.2381647","article-title":"Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression","volume":"65","author":"Charalampous","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annonc.2025.01.022_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1495233","article-title":"Anti-BCMA and GPRC5D bispecific antibodies in relapsed\/refractory primary plasma cell leukemia: a case report","volume":"15","author":"Bernardi","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.annonc.2025.01.022_bib104","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.346","article-title":"A\u00a0phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Med"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.01.022_bib105","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1182\/blood-2024-208780","article-title":"Impact of T-cell redirecting therapies on survival outcomes in ultra-high-risk multiple myeloma and plasma cell leukemia","volume":"144","author":"Elmaleh","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.annonc.2025.01.022_bib106","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from\u00a0the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib107","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.annonc.2025.01.022_bib108","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.01.022_bib109","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1182\/blood-2024-200847","article-title":"A\u00a0phase 2 study of CART-ASCT-CART2 sandwich regimen treatment in patients with primary plasma cell leukemia","volume":"144","author":"Xu","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.01.022_bib110","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1182\/blood-2024-211626","article-title":"A\u00a0comparative study of plasma cell detection by peripheral smear and peripheral blood flow cytometry","volume":"144","author":"Bohra","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.annonc.2025.01.022_bib111","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.22.01226","article-title":"More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma","volume":"41","author":"Jelinek","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.annonc.2025.01.022_bib112","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.annonc.2025.01.022_bib113","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2025.01.022_bib114","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.22.02114","article-title":"How we manage newly diagnosed multiple myeloma with circulating tumor cells","volume":"41","author":"van de Donk","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.annonc.2025.01.022_bib115","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1200\/JCO.21.01217","article-title":"Identification of high-risk multiple myeloma with a plasma cell leukemia-like transcriptomic profile","volume":"40","author":"Hofste Op Bruinink","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.01.022_bib116","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A\u00a0validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.annonc.2025.01.022_bib117","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/leu.2012.127","article-title":"A\u00a0gene expression signature for high-risk multiple myeloma","volume":"26","author":"Kuiper","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.annonc.2025.01.022_bib118","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib119","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS)","volume":"291","author":"Messiou","year":"2019","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00256-021-03755-2","article-title":"Myeloma Response Assessment and Diagnosis System (MY-RADS): strategies for practice implementation","volume":"51","author":"Mulligan","year":"2022","journal-title":"Skeletal Radiol"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib121","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13244-022-01253-0","article-title":"Implementation of whole-body MRI (MY-RADS) within the OPTIMUM\/MUKnine multi-centre clinical trial for patients with myeloma","volume":"13","author":"Rata","year":"2022","journal-title":"Insights Imaging"},{"issue":"10","key":"10.1016\/j.annonc.2025.01.022_bib122","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/ajh.27425","article-title":"Central nervous system multiple myeloma: a real-world multi-institutional study of the Greek Myeloma Study Group","volume":"99","author":"Katodritou","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.annonc.2025.01.022_bib123","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.annonc.2025.01.022_bib124","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.annonc.2025.01.022_bib125","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2025.01.022_bib126","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1080\/10428194.2024.2395440","article-title":"Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria","volume":"65","author":"Zhukovsky","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.annonc.2025.01.022_bib127","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/cncr.35202","article-title":"Detection of circulating plasma cells in peripheral blood using deep learning-based morphological analysis","volume":"130","author":"Chen","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2025.01.022_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107090","article-title":"Identification of signature genes and drug candidates for primary plasma cell leukemia: an integrated system biology approach","volume":"162","author":"Chaudhary","year":"2023","journal-title":"Comput Biol Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425000584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425000584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T06:51:06Z","timestamp":1744267866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425000584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":128,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0923753425000584"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.01.022","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Myeloma Network Group review and consensus statement on primary plasma cell leukemia","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}